MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4+ T cells in vivo
There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capacity of B cells to specifically activate tumour-specific CD4+ T cells in vivo via TCR-dependent interac...
Saved in:
| Main Authors: | Thomas V. Guy, Alexandra M. Terry, Helen M. McGuire, Elena Shklovskaya, Barbara Fazekas de St Groth |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290799 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physiological and therapeutic relevance of T cell receptor-mediated antigen trogocytosis
by: Nuria Martinez-Martin, et al.
Published: (2024-10-01) -
Distinct T-cell receptor (TCR) gene segment usage and MHC-restriction between foetal and adult thymus
by: Jasmine Rowell, et al.
Published: (2024-12-01) -
New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells
by: Zélia Silva, et al.
Published: (2024-11-01) -
NetMHCphosPan - Pan-specific prediction of MHC class I antigen presentation of phosphorylated ligands
by: Carina Thusgaard Refsgaard, et al.
Published: (2021-10-01) -
Revealing novel CD8+ T-cell epitopes from the H5N1 avian influenza virus in HBW/B1 haplotype ducks
by: Wanlin Jiao, et al.
Published: (2024-12-01)